Relapsing Polychondritis

Comprehensive Clinical Guide: Relapsing Polychondritis (RP)

Relapsing Polychondritis (RP) is a rare, systemic, immune-mediated inflammatory disorder characterized by recurrent episodes of inflammation and subsequent destruction of cartilaginous structures throughout the body. While it most frequently targets the auricular (ear) and nasal cartilage, the disease has a systemic reach, potentially affecting the ocular, cardiovascular, respiratory, and musculoskeletal systems.

1. Clinical Definition and Overview

Relapsing Polychondritis is classified as a rare systemic vasculitis. It is a chronic, episodic condition that fluctuates between periods of acute inflammation and relative quiescence. The hallmark of the disease is the progressive degradation of proteoglycan-rich tissues, specifically hyaline and elastic cartilage.

The prevalence of RP is estimated at approximately 3.5 to 4.5 per million population, with an equal sex distribution. While it can manifest at any age, the peak incidence occurs between the fourth and sixth decades of life.

2. Etiology and Pathophysiology

The exact etiology of Relapsing Polychondritis remains idiopathic; however, it is widely accepted as an autoimmune process. The disease mechanism involves a breakdown of self-tolerance, leading to the production of autoantibodies against type II collagen (the primary component of articular cartilage) and matrilin-1.

The Mechanism of Destruction

1. Antigen Exposure: The immune system recognizes cartilage-specific proteins (specifically Type II collagen) as foreign.
2. Cellular Infiltration: T-lymphocytes and macrophages infiltrate the perichondrium.
3. Cytokine Cascade: There is a significant upregulation of pro-inflammatory cytokines, specifically TNF-alpha, IL-1, and IL-6.
4. Enzymatic Degradation: Matrix metalloproteinases (MMPs) and reactive oxygen species are released, leading to the rapid dissolution of the cartilage matrix.
5. Fibrotic Remodeling: As inflammation subsides, the destroyed cartilage is often replaced by fibrous connective tissue, leading to the characteristic "floppy" appearance of affected anatomical structures (e.g., saddle-nose deformity, cauliflower ear).

3. Clinical Presentation and Staging

RP is notoriously difficult to diagnose in its early stages due to its protean manifestations. Patients often present with localized symptoms that may be misdiagnosed as simple infections or trauma.

Standard Clinical Indicators

The McAdam Criteria (Diagnostic Framework)

The diagnosis of RP is clinical, often utilizing the McAdam criteria. A definitive diagnosis is typically reached if the patient exhibits three or more of the following:
* Bilateral auricular chondritis.
* Non-erosive inflammatory polyarthritis.
* Nasal chondritis.
* Ocular inflammation (conjunctivitis, scleritis, uveitis).
* Respiratory tract chondritis (laryngeal or tracheal).
* Vestibulocochlear dysfunction (hearing loss, tinnitus, or vertigo).

4. Differential Diagnosis

Because RP mimics other systemic inflammatory conditions, a rigorous differential diagnosis is mandatory. Clinicians must rule out:

1. Granulomatosis with Polyangiitis (GPA): Often involves the upper respiratory tract but typically shows ANCA positivity and distinct histological features.
2. Infectious Perichondritis: Usually unilateral and associated with trauma or piercing; lacks the systemic involvement of RP.
3. Sarcoidosis: Can cause nasal and ocular symptoms but usually presents with characteristic hilar lymphadenopathy.
4. Rheumatoid Arthritis: While joint involvement is similar, RA typically does not affect the auricular or nasal cartilage.
5. Cogan’s Syndrome: Features ocular inflammation and vestibulocochlear symptoms but lacks the cartilage destruction characteristic of RP.

5. Diagnostic Testing and Evaluation

There is no single "gold standard" laboratory test for RP. Diagnosis relies on a combination of clinical findings, imaging, and biopsy.

Key Diagnostic Modalities

• Laboratory Markers: Acute phase reactants (ESR and CRP) are typically elevated during flares. Anti-type II collagen antibodies may be present but are not specific.
• Imaging:
  • CT/MRI: Essential for assessing the extent of airway involvement (tracheobronchomalacia).
  • PET/CT: Highly sensitive for identifying areas of silent, active cartilaginous inflammation.
• Biopsy: Histopathology of affected cartilage shows loss of basophilia, perichondrial inflammation, and replacement by fibrous tissue. This is reserved for ambiguous cases due to the risk of poor wound healing in inflamed cartilage.
• Pulmonary Function Tests (PFTs): Vital for detecting subclinical airway obstruction.

6. Management and Therapeutic Strategy

Treatment is dictated by the severity of the disease. RP is a chronic condition, and management must be individualized.

Pharmacological Interventions

1. Mild Disease: Non-steroidal anti-inflammatory drugs (NSAIDs) and dapsone.
2. Moderate Disease: Systemic corticosteroids (prednisone) are the cornerstone of therapy for controlling acute flares.
3. Severe/Systemic Disease: Steroid-sparing agents are required, including:
   • Methotrexate
   • Azathioprine
   • Cyclophosphamide (for severe vasculitis or organ-threatening airway involvement)
   • Biologics (TNF-inhibitors like Infliximab, or IL-6 inhibitors like Tocilizumab)

7. Risks, Contraindications, and Long-Term Prognosis

Complications

• Airway Collapse: The most lethal complication. Tracheobronchomalacia can lead to respiratory failure.
• Cardiovascular: Aortic valve insufficiency and aortic aneurysms are significant causes of morbidity.
• Ocular Damage: Permanent vision loss if scleritis is left untreated.

Prognosis

The 5-year survival rate is approximately 70-80%. The primary causes of mortality are respiratory tract involvement (airway collapse) and cardiovascular complications (aortic rupture or valvular disease). Early intervention with aggressive immunosuppression is the best predictor of a favorable long-term outcome.

8. Frequently Asked Questions (FAQ)

1. Is Relapsing Polychondritis contagious?

No. RP is an autoimmune, non-infectious, systemic disease. It cannot be transmitted from person to person.

2. Why does the earlobe get spared in RP?

The earlobe is composed of adipose and connective tissue rather than cartilage. Since RP specifically targets cartilaginous structures, the earlobe remains unaffected.

3. Can Relapsing Polychondritis be cured?

Currently, there is no known cure. However, with appropriate medical management, patients can achieve long-term remission and maintain a good quality of life.

4. What is the most dangerous symptom of RP?

Respiratory involvement. Inflammation of the trachea and bronchi can lead to narrowing of the airway (stenosis) and life-threatening collapse.

5. Are there specific genetic markers for RP?

While there is an association with HLA-DR4, there is no single genetic test that can confirm the diagnosis.

6. Does diet play a role in managing RP?

There is no specific "RP diet." However, an anti-inflammatory diet is generally encouraged to support overall health while managing the side effects of chronic steroid use.

7. How often should I see a specialist?

Patients with active disease require close monitoring by a rheumatologist, often monthly, with periodic evaluations by an otolaryngologist and pulmonologist.

8. Can RP affect the heart?

Yes. RP can cause inflammation of the aorta (aortitis), which may lead to aneurysms or heart valve problems.

9. Is surgery recommended for the "saddle-nose" deformity?

Surgical reconstruction is generally avoided during active disease, as the underlying inflammatory process can cause the graft to fail or the condition to recur in the surgical site.

10. What is the role of biologics in treatment?

Biologics are increasingly used for patients who are refractory to standard immunosuppressants or who cannot tolerate high doses of corticosteroids. They target specific inflammatory pathways like TNF-alpha or IL-6.

9. Conclusion for Clinicians

Relapsing Polychondritis is a complex, multi-systemic disorder that demands a high index of clinical suspicion. Early diagnosis, particularly the identification of subclinical airway involvement, is paramount to preventing catastrophic outcomes. As we move toward a more personalized medicine approach, the integration of advanced imaging and targeted biological therapies continues to improve the therapeutic landscape for these patients.

Disclaimer: This guide is intended for medical informational purposes only and does not replace the professional judgment of a healthcare provider. Clinical decisions should always be based on individual patient assessment.